Industry

Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU across Europe to earlier use in HER2 positive metastatic breast cancer Based on groundbreaking DESTINY-Breast03 results in which ENHERTU demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1) TOKYO & MUNICH, Germany–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: … [Read more…]

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile (PI Dr. Pablo González). Study results will … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–For decades, the treatment for a young child with a broken femur has been the same: a surgically placed spica cast, commonly known as a body cast. But now, thanks to a new study led by Children’s Hospital Los Angeles, the days of casting these injuries may soon be over. The study, led … [Read more…]

Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week data demonstrate continued improvements in repigmentation with longer duration of treatment Investor conference call and webcast scheduled for July 19, 2022, … [Read more…]

GUILFORD, Conn.–(BUSINESS WIRE)–Jul. 18, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next generation single molecule protein sequencing, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a conference call to … [Read more…]

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2022 of $1.13 per share on the company’s common stock. The dividend is payable on September 6, 2022 to shareholders of record at the close of business on August 23, 2022. The … [Read more…]

Expansion Will Grow Service Area to More Than 70 Countries Throughout Europe, the Middle East and Africa BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp® (NYSE: LH), a leading global life sciences company, today announced an expansion of its automated clinical trial kit production line in Mechelen, Belgium. Once completed, expansion will allow for clinical trial test kits to be … [Read more…]

HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2022 on Thursday, July 28, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. “This is an important step forward for members of … [Read more…]

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common shares at a price to the public of US$9.25 per common share. The total gross proceeds to the Company were … [Read more…]